Scenarios that move COR
Cencora, Inc. Common Stock
Scenarios that move COR: 14 analyses, 14 positive, 0 negative.
- · Opus Genetics receives FDA approval for presbyopia eye drop — ▲ · impact +7 · confidence low · horizon quarters
- · FDA expands ImmunityBio's Anktiva label for bladder cancer — ▲ · impact +9 · confidence low · horizon quarters
- · Mirum's Livmarli meets Phase III goal in ultra-rare liver diseases — ▲ · impact +10 · confidence low · horizon quarters
- · Roche reports positive Phase III eye drug data, FDA accepts BLA — ▲ · impact +30 · confidence low · horizon quarters
- · HALO wins court order blocking Merck's European Keytruda SC — ▲ · impact +17 · confidence low · horizon quarters
- · Lilly reports strong weight loss results for new drug — ▲ · impact +45 · confidence low · horizon quarters
- · DBV Technologies files FDA BLA for VIASKIN Peanut patch — ▲ · impact +8 · confidence low · horizon quarters
- · Mirum's Brelovitug meets goal in Phase III AZURE-1 study — ▲ · impact +10 · confidence low · horizon quarters
- · Kodiak Sciences shares soar 178% on positive wet AMD data — ▲ · impact +12 · confidence low · horizon quarters
- · Zymeworks updates 2026 guidance after Theravance acquisition — ▲ · impact +8 · confidence low · horizon quarters
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▲ · impact +38 · confidence low · horizon quarters
- · CHMP backs CORT's Lifyorli combo for ovarian cancer — ▲ · impact +8 · confidence low · horizon quarters
- · FDA approves Isembyld for spinal muscular atrophy treatment — ▲ · impact +12 · confidence low · horizon quarters
- · Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial — ▲ · confidence low